Tandem Diabetes Care Stock News

SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2023 results af

Battered stocks to buy usually represent the exclusive avenue of the extreme speculator. As many beginner investors often find out, you don't want to take the buy low, sell high adage blindly without

Tandem Diabetes Care experienced a Q1 2023 financial downturn, yet expects a 10%-12% annual growth rate. Despite weak recent stock performance, Tandem exhibits a robust growth profile but faces profit

Ordinarily, a blisteringly hot jobs report wouldn't inspire discussions about stocks to buy before crash. Essentially, the latest employment readout suggested that more money chases after fewer goods.

Novo Nordisk's expertise in diabetes care is about to produce another promising medicine. Tandem Diabetes Care is looking to take advantage of the vast insulin-pump opportunity.

Investors continue to be optimistic about Tandem Diabetes (TNDM) based on the strong performance of the t:slim X2 insulin pump.

According to Tandem Diabetes (TNDM), Q1 revenues are in line with the high end of its expectations.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Susan Morrison - Executive Vice President and Chief Administrative Officer John S

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.23 per share a year ago.

Axsome is expecting important developments that should improve its already-bright prospects. Tandem's innovative insulin pump should allow it to capture a larger share of the diabetes market.

SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2023 results aft

Tandem Diabetes (TNDM) is now increasing its renewal numbers both in volume and rates.

Tandem Diabetes (TNDM) demonstrated positive results from the clinical trial of advancing its Control-IQ technology to younger age group patients.

Tandem Diabetes Care is having issues on the top and bottom lines. However, the medical device maker still boasts plenty of growth avenues.

Tandem Diabetes (TNDM) Q4 GAAP sales reflect an accounting deferral related to the recent introduction of the company's Tandem Choice program in the United States.